Message-Based Psychotherapy and Digital Treatment Sequences for Depression

Sponsor
Talkspace (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04513080
Collaborator
University of Washington (Other)
1,000
1
10
51
19.6

Study Details

Study Description

Brief Summary

This partnership between Talkspace and the UW ALACRITY Center will determine how effective unlimited text-based psychotherapy for depression is when compared to once-a-week psychotherapy. This study will also determine what the best treatment options are for people who are not responding well to either unlimited texting or weekly psychotherapy. The results of this study will be a new product version of message-based care that can tailor psychotherapy intensity based on the needs of future consumers with depression.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Video-chat psychotherapy (VCP)
  • Behavioral: Message-based psychotherapy (MBP)
  • Behavioral: Message-based psychotherapy with monthly video chat (Premium Plan)
  • Behavioral: Message-based psychotherapy with weekly video chat (Ultimate Plan)
N/A

Detailed Description

This is a fast track SBIR proposal that will (1) test the effectiveness of daily, message-based psychotherapy (MBP) for depression, compared to traditionally delivered, video-chat psychotherapy (VCP) and (2) develop an evidence-based treatment sequence for those who do not respond to either daily MBP or VCP.

Phase 1 consists of a pilot study to determine the best incentive model to retain a sample of people 18 years old and older with depression into a SMART trial. Information from this pilot will inform the retention strategy for Phase 2.

Phase 2 is a 12-week, randomized clinical trial using a SMART design to test the following aims: 1. Determine the relative effectiveness of daily MBP compared to weekly VCP in treating symptoms of depression and improving social functioning; 2. For those who fail to respond to 6 weeks of weekly VCP only, determine whether the addition of daily messaging, or a switch to monthly video-chat plus daily messaging improves depression and functional outcomes; and 3. For those who fail to respond to 6 weeks of daily MBP, whether the addition of monthly video-chat or weekly video-chat improves outcomes. Participants will provide data on mood, activity, and functioning, and we will collect data on use of treatment (texts and sessions), and working alliance.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Phase 1 will test the effectiveness of two forms of participant retention methods into a SMART (sequential, multiple assignment, randomized). In Phase 1, participants (n=200) will be randomized to an incentive level and then randomized to treatment arms. Phase 2 (n=1000) will be the subsequent SMART design comparing message-based psychotherapy (MBP) to video-chat psychotherapy (VCP) in level 1 and for those who do not respond to care after 6 weeks, those participants will be randomized to either MBP+monthly VCP or MBP+weekly VCP.Phase 1 will test the effectiveness of two forms of participant retention methods into a SMART (sequential, multiple assignment, randomized). In Phase 1, participants (n=200) will be randomized to an incentive level and then randomized to treatment arms. Phase 2 (n=1000) will be the subsequent SMART design comparing message-based psychotherapy (MBP) to video-chat psychotherapy (VCP) in level 1 and for those who do not respond to care after 6 weeks, those participants will be randomized to either MBP+monthly VCP or MBP+weekly VCP.
Masking:
Single (Outcomes Assessor)
Masking Description:
In Phase 1, participants will be masked to the incentive condition to which they are randomized but will be aware of which treatment condition they are receiving.
Primary Purpose:
Treatment
Official Title:
Message-Based Psychotherapy and Digital Treatment Sequences for Depression
Actual Study Start Date :
Mar 2, 2020
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Phase 1, Level 1: Incentive 1 + Video-chat psychotherapy

In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.

Behavioral: Video-chat psychotherapy (VCP)
Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.

Experimental: Phase 1, Level 1: Incentive 2 + Video-chat psychotherapy (VCP)

In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.

Behavioral: Video-chat psychotherapy (VCP)
Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.

Experimental: Phase 1, Level 2: MBP with weekly VCP

Phase 1 participants who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm), monthly VCP with unlimited MBP (switch/minimal augmentation arm).

Behavioral: Message-based psychotherapy with weekly video chat (Ultimate Plan)
The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.

Experimental: Phase 1 Level 2: MBP with monthly VCP

Phase 1 participants randomized to VCP who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm) or monthly VCP with unlimited MBP (switch/minimal augmentation arm).

Behavioral: Message-based psychotherapy with monthly video chat (Premium Plan)
The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.

Experimental: Phase 2 Level 1: Message-Based Psychotherapy (MBP)

Phase 2 participants who respond to MBP after 6 weeks of care will continue in this condition for another 6 weeks. Participants who do not respond by week 6 will be randomized to one of two augmentation arms, MBP plus monthly video chat (Premium Plan: PP) or MBP plus weekly video chat (Ultimate Plan: UP) for another 6 weeks of care.

Behavioral: Message-based psychotherapy (MBP)
Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.

Experimental: Phase 2, Level 1: Video-Chat Psychotherapy (VCP)

Phase 2: Weekly psychotherapy appointments that last between 30-45 minutes. Participants who do not respond to this model will be randomized to switch (PP) or augment (UP) VCP.

Behavioral: Video-chat psychotherapy (VCP)
Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.

Experimental: Phase 2, Level 2: MBP with monthly VCP

Phase 2: This intervention will serve as the "switch arm" for participants who do not respond to VCP by week 6, and one of two augmentation arms for participants who do not respond to MBP. The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist.

Behavioral: Message-based psychotherapy with monthly video chat (Premium Plan)
The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.

Experimental: Phase 2, Level 2: MBP with weekly VCP

Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.

Behavioral: Message-based psychotherapy with weekly video chat (Ultimate Plan)
The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.

Experimental: Phase 1, Level 1: Incentive 1 + Message-based psychotherapy

In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.

Behavioral: Message-based psychotherapy (MBP)
Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.

Experimental: Phase 1, Level 1: Incentive 2 + Message-based psychotherapy

In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.

Behavioral: Message-based psychotherapy (MBP)
Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.

Outcome Measures

Primary Outcome Measures

  1. Change in Neuro-QoL - Ability to Participate in Social Roles and Activities [Change from Baseline Neuro-QoL at 6 weeks and 12 weeks after treatment starts]

    Phase 2: The Neuro-QoL is used to assess ability to participate in social roles and activities and will be used to assess functioning and disability.

  2. Change in Patient Health Questionnaire (PHQ-9) [Change from Baseline PHQ-9 at 6 weeks and 12 weeks after treatment starts]

    Phase 2: The PHQ-9 consists of 9 depression items and one disability item. Each time is associated with a DMS symptom of depression, which the participant rates whether or not they have experienced the symptom over the last two weeks, with severity rating of 0-3. It is one of the few measures that is brief (it takes less than one minute to give) and has been found to have excellent sensitivity to change over time.

Secondary Outcome Measures

  1. Change in Generalized Anxiety Disorder (GAD-7) [Change from Baseline GAD-7 at 6 weeks and 12 weeks after treatment starts]

    Phase 2: To assess for co-occurring anxiety, we will use the GAD-7, a 7- item screener for generalized anxiety. It consists of items related to GAD. Participants rate on a scale of 0-3 how much they have experienced in the last two weeks. The scale is a valid screener for GAD.

Other Outcome Measures

  1. Expectations about Treatment (TRS) [Baseline]

    Phase 2: Expectations about treatment can influence outcomes. To assess participant expectations, we will administer the Treatment Rationale Scale (TRS), a 4-item scale administered before the 2nd and last session. The scale assesses patient expectations about the success of treatment.

  2. Experience of Care and Health Outcomes Survey (ECHO) [12 weeks after treatment starts]

    Phase 2: ECHO items assess whether consumers received timely treatment, enough information to support self-management, and were involved in treatment as much as they wanted. ECHO is a reliable instrument with alpha = .85.

  3. Working Alliance Inventory (WAI) [12 weeks after treatment starts]

    Phase 2: The WAI is a 12-item measure of therapeutic alliance (relationship between the consumer and therapist or coach). It is a reliable measure of alliance, with alpha = .92.

  4. Tailoring Variable - Clinician-Administered PHQ-9 [6 weeks after treatment starts]

    Phase 2: To determine whether patients move to level II treatment we will used clinician administered PHQ9 at week 6 of treatment. Anyone falling below a 50% change in baseline PHQ9 scores will be switch to either the Platinum Plan (PP) condition or Ultimate Plan (UP) condition.

  5. Treatment Use Variables [12 weeks after treatment starts]

    Phase 2: Number of sessions attended

  6. Treatment Use Variables [12 weeks after treatment starts]

    Phase 2: Number of messages sent

  7. Treatment Use Variables [12 weeks after treatment starts]

    Phase 2: Time between patient and psychotherapist contact

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion and exclusion criteria are the same for Phase 1 and Phase 2.

Inclusion Criteria:
  • 18 years old or older

  • English or Spanish speaking

  • Live in the United States

  • Score of 10 or greater on the PHQ-9 screening

  • Receive a diagnosis of depression from a Talkspace intake clinician

Exclusion Criteria:
  • Under the age of 18

  • Non-English or Spanish speaking

  • Do not meet criteria for a depressive disorder

  • Participants with active suicidal ideation or with a primary diagnosis of psychosis will also be excluded and referred to intensive care.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Talkspace New York New York United States 10025

Sponsors and Collaborators

  • Talkspace
  • University of Washington

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Thomas Derrick Hull, VP, Clinical Research & Development, Talkspace
ClinicalTrials.gov Identifier:
NCT04513080
Other Study ID Numbers:
  • STUDY00010391
First Posted:
Aug 14, 2020
Last Update Posted:
Apr 7, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2022